CSL Seqirus

As one of the largest influenza vaccine providers in the world, CSL Seqirus is a major contributor to the prevention of influenza globally and a transcontinental partner in pandemic preparedness. CSL Seqirus operates state-of-the-art production facilities in the U.S., the UK and Australia, and manufactures influenza vaccines using both egg-based and cell-based technologies. It has leading R&D capabilities, a broad portfolio of differentiated products and a commercial presence in more than 20 countries.

NEWS ARTICLES

National Academy of Medicine: “An effective pandemic preparedness and response system is possible”

STAT News: “Push to double up on Covid booster and flu shot may have a downside, experts caution”

U.S. News: “Another Reason to Get the Flu Shot: Lowered Risk for Stroke”